In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025$17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback